Background and purpose: A prostamide analogue, bimatoprost, has been shown to be effective in reducing intraocular pressure, but its precise mechanism of action remains unclear. Hence, to elucidate the molecular mechanisms of this effect of bimatoprost, we focused on pharmacologically characterizing prostaglandin FP receptor (FP) and FP receptor variant (altFP) complexes. Experimental approach: FP receptor mRNA variants were identified by reverse transcription-polymerase chain reaction. The FP-altFP4 heterodimers were established in HEK293/EBNA cells co-expressing FP and altFP4 receptor variants. A fluorometric imaging plate reader was used to study Ca 2 þ mobilization. Upregulation of cysteine-rich angiogenic protein 61 (Cyr61) mRNA was measured by Northern blot analysis, and phosphorylation of myosin light chain (MLC) by western analysis. Key results: Six splicing variants of FP receptor mRNA were identified in human ocular tissues. Immunoprecipitation confirmed that the FP receptor is dimerized with altFP4 receptors in HEK293/EBNA cells co-expressing FP and altFP4 receptors. In the studies of the kinetic profile for Ca 2 þ mobilization, prostaglandin F 2a (PGF 2a ) elicited a rapid increase in intracellular Ca 2 þ followed by a steady state phase. In contrast, bimatoprost elicited an immediate increase in intracellular Ca 2 þ followed by a second phase. The prostamide antagonist, AGN211335, selectively and dose-dependently inhibited the bimatoprost-initiated second phase of Ca 2 þ mobilization, Cyr61 mRNA upregulation and MLC phosphorylation, but did not block the action of PGF 2a . Conclusion and implications: Bimatoprost lacks effects on the FP receptor but may interact with the FP-altFP receptor heterodimer to induce alterations in second messenger signalling. Hence, FP-altFP complexes may represent the underlying basis of bimatoprost pharmacology.
Introduction
Prostaglandin F 2a (PGF 2a ) is a product of cyclooxygenasecatalysed metabolism of arachidonic acid (Smith et al., 1991) . It has been identified to be an endogenous ligand of prostaglandin FP receptors. Activation of FP receptors initiated by ligand binding triggers G a q protein-coupled mechanisms involving Ca 2 þ signalling, IP 3 turnover and activation of protein kinase C (Toh et al., 1995) . PGF 2a has diverse physiological actions that include causing smooth muscle contraction (Horton and Poyser, 1976) , stimulating DNA synthesis and cell proliferation, and cardiac myocyte hypertrophy (Adams et al., 1996) . Importantly, PGF 2a analogues have been used clinically to reduce ocular hypertension (Woodward et al., 1993) . Although the precise mechanisms involved remain unclear, the effects of PGF 2a analogues on intraocular pressure (IOP) principally involve an increase in uveoscleral outflow of aqueous humor. These events involve secretion of metalloproteinases by ciliary smooth muscle cells and remodelling of the extracellular matrix with a resultant widening of intermuscular spaces (Gaton et al., 2001; Weinreb and Lindsey, 2002; Richter et al., 2003) . In contrast to prostaglandin F 2a , prostamides (prostaglandin ethanolamides) were recently identified as a new class of compounds that was formed from anandamide via metabolic transformation catalysed by cyclooxygenase-2 (Yu et al., 1997; Burstein et al., 2000; Kozak et al., 2001; Koda et al., 2003) . Although their physiological actions have not been fully investigated, a synthetic prostamide analogue (bimatoprost) has been shown to be very effective in reducing IOP by increasing both uveosceral and trabecular outflow of aqueous humor (Woodward et al., 2001) . The activities of prostamides as endogenous ligands at prostaglandin receptor(s) have been investigated, but have been shown to exert no meaningful activity (Berglund et al., 1999; Woodward et al., 2001; Ross et al., 2002; Matias et al., 2004) . Studies on their metabolic rate clearly demonstrate that prostamides and their synthetic analogue bimatoprost exert their in vitro pharmacological effects (Matias et al., 2004) and ocular hypotensive effects as the intact molecule . Experimental evidence suggests that prostamides may act as endogenous ligands at their own receptors (prostamide receptors) (Woodward et al., 2001 Matias et al., 2004) . Nevertheless, prostamide activity has not, so far, been demonstrated in the absence of FP receptor activity. However, results from studies on FP-knockout mice have shown that the effects of bimatoprost on IOP are dependent on an intact FP receptor gene (Crowston et al., 2005; Ota et al., 2005) ; a single application of bimatoprost did not reduce IOP in FP receptor knockout mice, indicating that FP signalling is required for the early IOP response to bimatoprost. This raised the possibility that bimatoprost may interact with FP receptor gene products, such as spliced variants of the FP receptor or FP receptor complexes, such as FP receptor dimerizing or oligomerizing with FP spliced variants or other receptors. It seemed reasonable, therefore, to investigate newly discovered alternative splicing variants of FP receptor mRNA for their potential to interact with bimatoprost.
Methods
Total RNA isolation Human eyes were obtained from the National Disease Research Interchange (NDRI, Philadelphia, USA). These eyes were hemisected along the ora serata to expose the posterior chamber of the anterior segment. After the lens had been removed by clipping the zonules, the ciliary body was peeled away from the sclera and placed in ice-cold phosphatebuffered saline.
Total RNA was isolated from human ciliary bodies and human embryonic kidney 293/Epstein-Barr nuclear antigen (HEK293/EBNA) cell lines using RNeasy Kit (Qiagen Inc., Valencia, CA, USA), according to the manufacturer's instruction. RNA concentrations were determined by u.v. spectrophotometry (Beckman DU640) at 260 nm, and stored at -80 1C.
Reverse transcription-polymerase chain reaction Using 2 mg of human total RNA, first-strand cDNA was synthesized by SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA). Samples, 20 mL, containing 2 mg of RNA, 100 ng random primers and 50 U reverse transcriptase were incubated at 42 1C for 50 min and terminated by 75 1C for 15 min.
The PCR buffer contained 40 mM Tricine-KOH (pH 9.2), 15 mM KOAc, 3.5 mM Mg(OAc) 2 , 0.2 mM of each dNTP, 0.2 mM upstream primer (p1: 5 0 -tgcaatgcaatcacaggaatt-3 0 ) and downstream primer (p2: 5 0 -cactccacagcattgactgg-3 0 ), and 1 U Advantage cDNA polymerase in a final volume of 50 mL. After an initial incubation for 5 min at 94 1C, samples were subjected to 35 cycles of 30 s at 94 1C, 30 s at 58 1C and 30 s at 72 1C in a PE9700 thermal cycler.
The PCR products were isolated from 1.5% low-melting agarose gel and subcloned into PCR II TOPO vector (Invitrogen). Sequence analysis was performed by Sequetech (Mountain View, CA, USA). Sequence alignments and analysis were done using the National Center for Biotechnology Information database.
Subcloning and plasmid transfection
Full-length FP and alternative splicing variant of prostaglandin FP receptor (altFP) receptor cDNAs were isolated and subcloned into retrovirus vector (Invitrogen). The plasmids were designated QhFP-wt and QhFP-alt. QhFP-wt or QhFP-alt were transfected into GP2-293 packaging cells. After 72 h, the supernatants containing virus were harvested and centrifuged at 800 g for 15 min to remove cell debris. Virus stock was titrated and stored at À80 1C. HEK293/EBNA cells were grown in 6-cm dishes containing Dulbecco's modified Eagle's medium with 10% fetal bovine serum. The cells were infected with QhFP-wt or QhFP-alt, or co-infected with both QhFP-wt and QhFP-alt in equal amounts of virus. After 24 h of infection, the virus-containing medium was removed and replaced with fresh medium containing hygromycin for cell clone selection. Hygromycin-resistant colonies were amplified and screened for expression of FP and altFP receptors. The established cell lines were maintained in the same media as the parental lines.
Epitope tagging of FP receptors and altFP receptors
Wild-type FP and altFP receptors were tagged at their amino termini with either two repeats of haemagglutinin (HA) nonapeptide (YPYDVPDYA) separated by a Gly residue or with two repeats of a Flag sequence (DYKDDDDK), also separated by a Gly residue. Because the FP receptors containing two Flag epitopes or HA epitopes at the amino terminus may not localize to the cell membrane (Fujino et al., 2000) , we introduced a prolactin signal peptide preceding the Flag sequence to create Pro-Flag-FP and preceding the HA sequence to create Pro-HA-altFP, according to methods previously described (Kolodziej and Young, 1991) . Pro-Flag-FP or Pro-HA-altFP cDNA encoded the amino terminus MDSKGSSQKGSRLL LLLVVSNLLLCQGVVS/DYKD DDKy or MDSKGSSQKGSRLLLLLVVSNLLLCQ GVVS/ YPYDVPD YAyrepresenting the prolactin signal peptide, signal peptidase site(/), Flag epitope-FP or HA epitope-altFP. The prolactin signal peptide was then cleaved by signal peptidase after expression. All of the tagged FP or altFP receptors were subcloned into lentivirus expression vector to create Lenti-Pro-Flag-FP and Lenti-Pro-HA-altFP expression plasmids. All of the plasmids were transfected into 293FT packaging cell lines. After 48 h transfection, the virus containing cell medium was collected, titered and stored at -80 1C. HEK293/EBNA cells were grown in 6-cm dishes containing Dulbecco's modified Eagle's medium with 10% fetal bovine serum. The cells were infected with an equal amount of virus. After 24 h of infection, the virus-containing medium was removed and replaced with fresh medium containing blasticidin for cell clone selection. Blasticidinresistant colonies were amplified and screened for expression of Flag-FP and HA-altFP receptors. The established cell lines were maintained in the same medium as the parental lines.
Northern blot analysis
Total RNA (10 mg) was denatured at 65 1C in RNA loading buffer (Ambion Inc., Austin, TX, USA) for 15 min and separated on 1.2% agarose gels containing 0.66 M formaldehyde. RNA loading was assessed by ethidium bromide staining of 28S and 18S ribosomal RNA bands. The relative intensities of 28S and 18S ribosomal RNA bands were used as internal controls to normalize the hybridizations. Human 1.4-kb Cyr61 ( þ 60 to þ 1459; GenBank accession no. AF003594) gene-specific DNA fragment was radiolabelled using an [a- 32 P]-dCTP and Klenow (Ambion Inc.). The blots were hybridized with the gene-specific probes in 50% formamide, 4 Â SSC, 1 Â Denhardt's solution, 50 mM sodium phosphate (pH 7.0), 1% sodium dodecyl sulphate (SDS), 50 mg mL À1 yeast tRNA and 0.5 mg mL À1 sodium pyrophosphate at 42 1C overnight and washed with SSC and 0.1% SDS twice at 42 1C and with 0.1 Â SSC and 0.1% SDS twice at 42 1C. The hybridized blots were exposed to phosphor screens, and the exposed screens were analysed in a PhosphorImager (Amersham Biosciences, Pittsburgh, PA, USA).
Immunoprecipitation and western blotting HEK293/EBNA cells were cultured in six-well plates. The confluent cells were harvested, washed and lysed in ice-cold lysis buffer containing 150 mM NaCl, 50 mM Tris HCl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 10 mM NaF, 10 mM sodium pyrophosphate, 100 mM sodium orthovanadate plus protease inhibitor mixture. The cell lysates were centrifuged at 14 000 g, at 4 1C, for 10 min. For immunoprecipitation, the supernatant fractions were collected and then incubated at 4 1C with HA11 (HA antibody) for 15 h. The incubation was continued for another 1 h in the presence of 50 mL of a 1:1 slurry of protein G agarose (Pierce, Rockford, IL, USA) at 4 1C. The beads were washed three times with lysis buffer, Laemmli sample buffer was added and the samples were boiled for 5 min and centrifuged at 12 000 g for 10 min. The supernatant fractions were subjected to western blot. In general, the supernatant fraction from immunoprecipitation or from cell lysates of transfected HEK293/EBNA cells were collected and electrophoresed on 10% SDS-polyacrylamide (SDS-PAGE) gels. Proteins were transferred to polyvinylidene fluoride membrane, and the blots were incubated with a 1:1000 dilution of a monoclonal HA11 or anti-Flag M2 antibody for 1 h at room temperature with rotation. The blots were washed three times and incubated for 1 h at room temperature with a 1:5000 dilution of a goat anti-mouse secondary antibody (Bio-Rad, Hercules, CA, USA) conjugated with horseradish peroxidase. After being washed three times, immunoreactivity of the samples was detected using an immune-star HRP developer system (Bio-Rad).
MLC phosphorylation HEK293/EBNA cells were cultured in 10-cm plates. The cells were deprived of nutrients in Opti-MEM for 24 h before being pretreated with 2-[3-(5-fluoro-2-propylcarbamoylmethoxybenzyl)-7-oxabicyclo[2.2.1]hept-2-yloxazole-4-carboxylic acid (4-cyclohexylbutyl) amide (AGN211335) for 15 min, followed by treatment with PGF 2a or bimatoprost for 30 min. The cell lysates were boiled for 5 min and centrifuged at 12 000 g for 10 min. The supernatant fractions were collected and electrophoresed on 10% SDS-PAGE gels.
Proteins were transferred to polyvinylidene fluoride membrane, and the blots were incubated with a 1:1000 dilution of a phosphorylated myosin light chain (MLC) antibody or MLC antibody for 16 h at 4 1C with rotation. The blots were washed three times and incubated for 1 h at room temperature with a 1:3000 dilution of a goat anti-rabbit secondary antibody (Bio-Rad) conjugated with horseradish peroxidase. After being washed three times, immunoreactivity of the samples was detected using an immune-star HRP developer system (Bio-Rad).
Calcium signal studies using a FLIPR instrument HEK293/EBNA cells were seeded at a density of 50 000 cells per well in Biocoat poly-D-lysine-coated black-well, clearbottom 96-well plates (Becton-Dickinson) and allowed to attach overnight. Before the assay, the cells were washed twice with Hank's balanced salt solution-HEPES buffer (without bicarbonate and phenol red, 20 mM HEPES, pH 7.4) using a Lab Systems Cellwash plate washer. After being subjected to 45 min of dye loading (fluo-4 AM, 2 mM) in the dark at 37 1C in 5% CO2 humidified atmosphere, the plates were washed three times with Hank's balanced salt solution-HEPES buffer to remove excess dye leaving 100 mL buffer in each well. Plates were equilibrated to 37 1C for 3 min prior to processing within the fluorometric imaging plate reader (FLIPR). The peak increase in fluorescence counts was recorded for each well. All data points were determined in triplicate. Mock-transfected cells (transfected with empty plasmid) were screened in parallel with FP-and alternative FP-co-transfected cells.
Prostamide antagonist pA 2 determination. The methods used to study the effects of antagonists of prostamide F 2a on bimatoprost-induced feline iridial stimulation and associated data analysis were identical
Identification and pharmacological characterization of FP and altFP complexes Y Liang et al to those previously described in more detail (Wan et al., 2007; Woodward et al., 2007) . Briefly, feline iridial tissue specimens were mounted vertically under 50-100 mg tension in 10 mL jacketed organ baths. These contained Krebs solution maintained at 37 1C and gassed with 95% O 2 and 5% CO 2 . Measurement of contractile activity was by means of force displacement transducers and was recorded on a polygraph chart recorder. After a 1-h equilibration period, vehicle and antagonist (AGN211335) were administered 30 min before the agonist dose-response curve was constructed. Agonist concentration-response curves were compared in the presence and absence of graded doses of antagonist (AGN211335 Human recombinant prostaglandin receptors. Studies on human recombinant prostaglandin receptors were as previously described Matias et al., 2004) . These involved Ca 2 þ signal studies and the use of a FLIPR instrument. The use of chimeric G protein cDNAs allowed responses to Gs-and Gi-coupled receptors to be measured as a Ca 2 þ signal. Thus, prostaglandin DP, EP 2 and EP 4 receptor cDNAs were co-transfected with chimeric Gqs cDNA, and EP 3 receptor cDNA was co-transfected with chimeric Gqi cDNA (Molecular Devices, Sunnyvale, CA, USA), each containing a haemagluttanin (HA) epitope to detect protein expression.
Stable transfection in HEK293/EBNA cells was achieved using the same vectors and Fugene 6 method as previously described. Stable transfectants were selected according to hygromycin resistance. FLIPR studies were performed as described in the previous section. AGN211335, 3 Â 10
was given as a 10 min pretreatment, vehicle control wells were pretreated with an equal volume of ethanol. Agonists used for each receptor are listed as follows: BW245C for DP; PGE 2 for EP 1-4 ; PGF 2a for FP; carbaprostacyclin for IP and U-46619 for IP receptors. The peak fluorescence change in each well containing the drug was expressed relative to the controls. No activity was observed at DP 1-2 , EP 1-4 , FP or IP receptors for 3 Â 10 À5 M AGN211335. AGN211335 was a TP antagonist with a k b of 101 nM. Activity at DP 2 (CRTH2) receptors was determined by externally using a proprietary FLIPR-based assay (GPCRProfiler, Millipore Corp., St Charles, MO, USA). The experimental conditions were identical to those employed at Allergan Inc.; PGD 2 was used as an agonist in this assay. AGN211335, 3 Â 10 À5 M, was found to have no activity at the DP 2 receptor.
Drugs AGN211335 was synthesized by Selcia Ltd (Ongar, Essex, UK). Bimatoprost and PGF 2a were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). All stock solutions were prepared in ethanol. Screening methods for the prostamide antagonist, AGN211335, were as previously described . 
Statistical analysis
Data are expressed as mean ± s.d. A significant difference between treatments was assessed by the one-way ANOVA, followed by a Bonferroni's post test procedure for multiple comparisons. Differences between treatments were considered to be significant if Po0.05. All statistical values were calculated using Graphpad Prism 4 software (GraphPad, San Diego, CA, USA).
Results

Identification of prostaglandin FP receptor variants in human eyes
To identify potential alternative mRNA splicing variants of the human FP receptor, reverse transcription-polymerase chain reaction analyses were performed using human ciliary body cDNA libraries and two FP-specific primers, p1, which is complementary to FP exon 2 sequence, and p2, which is complementary to FP exon 3 sequence. PCR products were subcloned and sequenced ( Figure 1a ). Sequence analysis showed that there are five additional exons between exon 2 and exon 3 (Figure 1b) . The human FP receptor gene contains three exons. The coding region of the FP receptor is located within exon 2 and exon 3. An insertion of the additional exon in the coding region causes frame shifts that lead to encode C terminus-truncated FP receptors (altFPs). Figure 2 shows the deduced amino-acid sequences of human FP (FP) and FP variants (altFPs). The FP and altFPs are identical up to amino acid 266 (leucine-266), at which point there is an insertion of additional exon A, exon B, exon C and exon E to form altFP1, altFP2, altFP4 and altFP5, respectively, and an insertion of two additional exons, exon A and B to form altFP3 and two additional exons, exon D and exon E to form altFP6. The amino-acid sequences of altFPs diverge from those of FP at leucine 266, which is close to the predicted carboxyl terminal end of TM6. For the human wild-type FP receptor, there are a total of 93 amino acids downstream of leucine-266, which constitute the third extracellular loop (À19 amino acids), TM7 (À22 amino acids) and the intracellular carboxyl terminus (À52 amino acids). A hydropathic profile analysis of FP and altFPs shows that all altFPs do not have a seventh TM domain and that its carboxyl terminus is extracellular. All altFPs were stably expressed in HEK293/EBNA cell lines. Cells expressing alternative FP receptor mRNA splicing variants were screened with FP ligands and bimatoprost using the FLIPR assay and could not be activated by 10 mM PGF 2a or bimatoprost (data not shown). This is entirely consistent with data from a previous study demonstrating that the first alternative variant of human FP receptor RNA (Vielhauer et al., 2004) is not the prostamide receptor. We thought that altFPs, as six-domain receptors, form dimers with FP receptors and function as regulators of the FP receptor. The next experiments were done to determine whether altFPs could form dimers with FP and to characterize their functions. Initial screening of the HEK293/EBNA cells co-transfected FP with each of altFPs (altFP1 and altFP6) showed that the co-transfected HEK293/EBNA cells responded to bimatoprost with a similar CA 2 þ mobilization profile to that of Ca 2 þ mobilization. As the longer C terminus of altFP4 provides a better prognosis for, perhaps, eventually designing a specific antibody to this isoform, we focused on characterizing the pharmacology of FP and its interaction with the altFP4 receptor heterodimer in the following studies.
Physical interactions between FP and altFP4 receptors
We initially developed stable cell lines of HEK293/EBNA cells expressing epitope-tagged FP and altFP receptors because this cell type has a high transfection efficiency and wide application in studies involving G protein-coupled receptors.
Infection of HEK293/EBNA cells with Lenti-Pro-HA-altFP4 or ( Figure 3a , lane 1), indicating that they represent altFP4 and FP receptor proteins. Figure 3a shows that the molecular weights of the bottom bands in both lane 2 and lane 3 were 33 kDa, which is very close to the calculated molecular mass of epitope-tagged altFP4 receptor, 34 kDa. Higher molecular weight top bands were also observed, a 66 kDa in lane 2, which is close to the calculated molecular weight mass of altFP4 homodimer, 68 kDa, and a 75 kDa in lane 3, which is very close to the calculated molecular weight mass of FPaltFP4 heterodimer, 74 kDa, suggesting that altFP4 receptors form homodimers ( Figure 3a , lane 2) and that FP and altFP4 co-transfection ( Figure 3a , lane 3) also formed heterodimers (FP molecular weight is higher than the altFP4 receptor). To clarify whether the higher molecular weight band (75 kDa; Figure 3a , lane 3) was derived from receptor heterodimerization or association with other unknown proteins, we conducted differential immunoprecipitation in which two different epitope-tagged receptors, HA-altFP4 and Flag-FP, were co-expressed and subjected to immunoprecipitation with anti-HA antibody, HA11, against HA-tag and then resolved on SDS-PAGE and immunoblotted with anti-Flag M2 an antibody against the Flag-tag FP receptor. As shown in Figure 3b (lane 3) when Flag-FP and HA-altFP4 receptors were co-expressed in HEK293/EBNA cells, Flag-FP receptors were clearly present in HA antibody-derived immunoprecipitates (Figure 3b, lane 3) , which further confirms that the 75-kDa band (Figure 3a, lane 3) is an FP-altFP4 heterodimer. When HEK293/EBNA cells were separately transfected with Flag-FP or HA-altFP4 receptors, no Flag-tagged receptor (Flag-FP) was immunoprecipitated with HA antibody (Figure 3b, lane 1) , and no HA-tagged receptor (HA-altFP4) was immunoblotted with Flag antibody (Figure 3b, lane 2) . Again, the Flag-tag FP receptor was seen only in the co-transfected HEK293/EBNA cells (Figure 3b, lane 3) .
Functional studies of FP receptor and altFP4 receptor dimerization. To investigate the effects of PGF 2a and bimatoprost on FP-altFP4 receptor heterodimer, we performed Ca 2 þ mobilization studies on HEK293/EBNA cells co-expressing epitopetagged HA-altFP4 and Flag-FP and HEK293/EBNA cells co-expressing FP and altFP4 receptors, using a FLIPR. Both HEK293/EBNA cell lines showed exactly the same kinetic profile for Ca 2 þ mobilization induced by PGF 2a or bimatoprost, indicating that epitopes contained in the amino terminus of the FP and altFP4 receptors did not disrupt the expression or functions of these receptors. In this study, we used HEK293/EBNA cell lines co-expressing FP and altFP4, expressing only FP and only altFP4 as cell models. Figure 4 shows that PGF 2a , 10 À7 M, activated FP-altFP4 (Figure 4aI) and the FP receptor (Figure 4bI ). There was no difference between only FP and FP-altFP4 in response to PGF 2a in terms of first peak of fluorescence counts and kinetic profiles. Both PGF 2a and bimatoprost at 10 À7 M activated the FP-altFP4 receptor heterodimer; the first peak of fluorescence counts for bimatoprost treatment were very close to those of PGF 2a (Figure 4aI and II). The kinetic profiles of real-time fluorescence traces for PGF 2a and bimatoprost treatments were different. PGF 2a elicited a robust and rapid increase in intracellular Ca 2 þ concentration followed by a steady-state phase within the time course of the experiment (600 s, count from the initiation of a rapid Ca 2 þ increase) (Figure 4aI ). In contrast, bimatoprost elicited an immediate and robust increase in intracellular Ca 2 þ concentration followed by a second phase Ca 2 þ wave within the time course of the experiment (600 s) (Figure 4aII ). This observation accords well with the results obtained in Ca 2 þ signalling studies in cat iris sphincter cells stimulated by bimatoprost. Bimatoprost was shown to elicit an immediate increase in intracellular Ca 2 þ concentration followed by a second Ca 2 þ wave, suggesting the existence of a native FP-altFP4 receptor heterodimer in cat iris sphincter cells (Spada et al., 2005) . Although PGF 2a markedly stimulated the wild-type FP receptor, bimatoprost produced not more than a residual effect (Figure 4bI and II). Neither PGF 2a nor bimatoprost activated the altFP4 receptor (Figure 4cI and II). To signal initiated by bimatoprost, Ca 2 þ -free buffer was used in the FLIPR assay. Both PGF 2a and bimatoprost elicited a rapid increase in intracellular Ca 2 þ concentration followed by an immediate return to baseline (Figure 4dI and II), suggesting that the bimatoprost-initiated second-phase Ca 2 þ mobilization may be attributed to store-operated Ca 2 þ influx. The data are summarized in Figure 4e . To determine whether the bimatoprost-initiated second-phase Ca 2 þ mobilization is due to Ca 2 þ release from a second intracellular Ca 2 þ store, thapsigargin, a Ca 2 þ -ATPase inhibitor, was used to deplete the endoplasmic reticulum Ca 2 þ store in the cells before bimatoprost treatment. The experiments showed that there is no further Ca 2 þ release upon bimatoprost treatment after endoplasmic reticulum Ca 2 þ stores were completely depleted, suggesting that bimatoprost-initiated second-phase Ca 2 þ mobilization may not be due to the release of Ca 2 þ from a second intracellular Ca 2 þ store (data not shown). (Figure 5aI-IV) . A summary of these data is shown in Figure 5c and d.
To determine whether the prostamide antagonist selectively blocks bimatoprost-induced biochemical signal cascades, we used the Cyr61 factor and MLC as biochemical signals to perform Cyr61 mRNA expression studies and MLC phosphorylation studies. Cyr61 has been well-characterized and regulates extracellular matrix remodelling through activation of matrix metalloproteinases . Phosphorylation of MLC causes ciliary muscle contraction with a resultant widening of intermuscular spaces (Ansari et al., 2003) . Increases in uveoscleral outflow result from extracellular matrix remodelling of the ciliary body and widened intermuscular spaces. Both PGF 2a and bimatoprost induced Cyr61 mRNA upregulation and MLC phosphorylation in HEK293/EBNA cells co-expressing FP and altFP4 receptors (Figures 6a and 7a) . Even though PGF 2a induced Cyr61 mRNA upregulation and MLC phosphorylation in HEK293/EBNA cells expressing the wild-type FP receptor, bimatoprost produced no effects (Figure 6b) . The prostamide antagonist, AGN211335, selectively blocked both bimatoprost-induced Cyr61 mRNA upregulation and bimatoprost-induced MLC phosphorylation in HEK293/EBNA cells co-expressing FP and altFP4 receptors, but not those induced by PGF 2a (Figures 6a and 7a) . We also investigated the effects of thapsigargin, as it activates store-operated channels independently of G protein-coupled receptors. However, it failed to induce Cyr61 mRNA upregulation (Figure 6b ), indicating that induction of Cyr61 mRNA upregulation requires more signal transduction pathways, possibly those involving the activation of G 12/13 and RhoA . These data fit well with the prostamide antagonist profile, which selectively inhibits bimatoprost-induced feline iris contraction, but not that produced by PGF 2a . (Figure 8a ). In marked contrast, and at all the doses used, AGN211335 produced a dose-dependent rightward shift of the prostamide dose-response curve (Figure 8b) . Thus, in a single preparation, AGN211335 selectively blocks the prostamide effect without altering the response to PGF 2a . As described in a previous study , the antagonist effects were never totally surmounted by 10 mM prostamide F 2a ; this has been attributed to off-target activity for prostamide F 2a at prostanoid FP receptor in the feline iris (Matias et al., 2004; Spada et al., 2005) . The AGN211335 antagonism of the prostamide F 2a was subjected to Schild analysis, as previously described . AGN211335 appeared to be a competitive antagonist with a pA 2 of 7.50. Finally, bimatoprost stimulation of feline iridial contraction did not occur in Ca 2 þ -free medium (Figure 8c ).
AGN211335 was screened for activity at other prostaglandin receptors using the full range of human recombinant receptors. No activity was observed at DP 1À2 , EP 1-4 , FP or IP receptors for 3 Â 10 À5 M AGN211335. AGN211335 is also a TP antagonist, with a k b of 101 nM, but is less potent as a TP receptor antagonist than the prototype prostamide antagonist AGN204396 . As functional TP receptors are not present in the feline iris preparation, this activity of AGN211335 does not interfere with the analysis of FP and prostamide receptor pharmacology.
Discussion
The pharmacology and physiological significance of truncated prostanoid receptors lacking an intracellular carboxyl terminus has remained obscure. Although transcripts for such truncated isoforms of FP (Vielhauer et al., 2004) and EP 1 (Okuda-Ashitaka et al., 1996) receptors were found in tissues, no ligand-dependent activation was observed (Okuda-Ashitaka et al., 1996; Vielhauer et al., 2004 (Gandolfi and Cimino, 2003; Woodward et al., 2003 Woodward et al., , 2007 Matias et al., 2004) .
There are a number of close correlations between the FP-altFP recombinant receptor model and prostamide pharmacology observed in cells, tissues and living animals. To date, prostamide F 2a and bimatoprost have been found to be active only in cells and tissues that express functional prostanoid FP receptors (Woodward et al., 2001 Liang et al., 2003; Richter et al., 2003; Matias et al., 2004) . This is consistent with the presence of FP-altFP heterodimers, which are responsive to prostamides and are indistinguishable from FP receptors with respect to PGF 2a effects. A close connection to the FP receptor gene is further indicated by studies claiming that the ocular hypotensive effect of bimatoprost is absent in -/-FP mice (Crowston et al., 2005; Ota et al., 2005) . Upregulation of Cyr61 appears to be a common upstream event in the initiation of ciliary muscle re-modelling and resultant increases in uveoscleral outflow, which are common to ocular hypotensive prostamides, FP and EP 2 receptor agonists Richter et al., 2003) . As human ciliary muscle cells are sensitive to bimatoprost, mRNA for the newly discovered altFP variants would be expected to be present in these cells, and this has been shown to be the case.
The discovery of selective antagonists has been of paramount importance in defining prostamide pharmacology. The prototypical prostamide antagonist AGN204396 was described in 2007 , but since then, rapid progress has occurred. Second-generation prostamide antagonists, such as AGN211334, which has been shown to block bimatoprost activity in human eye perfusion model (Wan et al., 2007) Thereafter, the Ca 2 þ signalling pathways diverge, as reflected by subsequent phases that are pharmacologically and qualitatively distinct. Antagonism of recombinant and native prostamide-sensitive FP-altFP heterodimeric receptors extends beyond Ca 2 þ signalling and smooth muscle contraction. Bimatoprost-induced Cyr61 mRNA upregulation in human ciliary smooth muscle cells is replicated in the FPaltFP4 heterodimeric receptor model and, importantly, is blocked by the prostamide antagonist AGN211335 . Finally, bimatoprost-induced MLC phosphorylation associated with FP-altFP4 heterodimeric receptors was blocked by AGN211335. Again, in the case of both MLC phosphorylation and Cyr61 upregulation, PGF 2a effects were not affected by pretreatment with the prostamide antagonist AGN211335. The action of prostamides has been found to involve mechanisms different from prostanoid FP receptor-mediated responses in the primate eye. First, the effect of bimatoprost in the ocular hypertensive monkey model of glaucoma (Gagliuso et al., 2004) has been shown to be additive to that of latanoprost, the FP receptor agonist prodrug (Resul et al., 1997) . This fits with the FP-altFP heterodimeric receptor concept, as divergent secondary Ca 2 þ signalling pathways may translate into an additive effect for prostamides and prostanoid FP receptor agonists on IOP. A pharmacological distinction between bimatoprost and latanoprost has also been made at the clinical level. Glaucomatous human subjects refractory to latanoprost treatment were found to be susceptible to bimatoprost, which produced a marked reduction of IOP (Gandolfi and Cimino, 2003) . This fits particularly well with the FP-altFP heterodimer prostamide receptor hypothesis as both bimatoprost and latanoprost would be expected to be active. The recent discovery that certain single-nucleotide polymorphisms associated with the FP receptor account for latanoprost insensitivity in the human eye (Sakurai et al., 2007) may be explained by
